The expert recommendations addressed clinical workflow, guideline creation, and reimbursement barriers to precision oncology.

The researchers previously received a single-patient approval to administer a second dose of the treatment in the study.

Investigators will evaluate the safety, tolerability, and exploratory signs of efficacy, including neurofilament light chain and SOD1 protein.

Treatment with the vaccine did not improve progression-free survival in patients with HPV16-positive cervical and anogenital tumors.